4 citations
,
September 2014 in “Elsevier eBooks” This review discusses the safety of dermatological medications used during pregnancy, highlighting that retinoids have strong teratogenic risks and should be used with caution; it reports no new clinical results.
October 2024 in “Internal Medicine” In this case report, a 47-year-old man experienced systemic hair loss after starting hemodialysis, which resolved after discontinuing the antipruritic drug nalfurafine, suggesting its role in causing hair follicle capillary regression.
73 citations
,
March 2014 in “Journal of The American Academy of Dermatology” Most dermatologic medications are safe during pregnancy and breastfeeding, but some should be avoided due to potential risks.
16 citations
,
May 2019 in “International Journal of Women's Dermatology” This study reviewed and categorized dermatological drugs for pregnancy and lactation according to new FDA labeling guidelines, which replaced simplistic letter categories with detailed information, aiming to improve prescribing decisions by addressing both maternal and paternal reproductive potential.
208 citations
,
July 2001 in “Journal of The American Academy of Dermatology” This review discusses the classification and diagnosis of pregnancy-related skin conditions and reports no new clinical findings.